Comparison of the Effects of a Brand-name Drug and Its Generic Drug on the Quality of Life of Alzheimer's Disease Patients

被引:3
|
作者
Sakakibara, Mikio [1 ,2 ,3 ]
Kido, Mitsuhiko [1 ,2 ,4 ]
Kuribayashi, Jun [2 ,4 ]
Okada, Hiroshi [1 ,2 ]
Igarashi, Ataru [5 ]
Kamei, Hiroyuki [3 ]
Nabeshima, Toshitaka [1 ,4 ]
机构
[1] Meijo Univ, NPO Japanese Drug Org Appropriate Use & Res, Fac Pharm, Nagoya, Aichi 4680073, Japan
[2] Meijo Univ, Sugi Pharm Co Ltd, Fac Pharm, Nagoya, Aichi 4680073, Japan
[3] Meijo Univ, Pharmaceut Hosp Lab, Fac Pharm, Nagoya, Aichi 4680073, Japan
[4] Meijo Univ, Dept Reg Pharmaceut Care & Sci, Fac Pharm, Nagoya, Aichi 4680073, Japan
[5] Univ Tokyo, Dept Drug Policy & Management, Grad Sch Pharmaceut Sci, Tokyo, Japan
关键词
Alzheimer disease; Donepezil hydrochloride; Generic drugs; Quality of life; EuroQo1-5; Dimension;
D O I
10.9758/cpn.2015.13.2.174
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Objective: The pharmacological effects of generic (GE) donepezil are the same as Aricept, its brand name counterpart. However, little is known as to whether these two drugs provide the same quality of life (QOL). The study subjects were patients with Alzheimer's disease who were taking donepezil hydrochloride tablets, and were selected by visiting either the local pharmacies or the patients' homes, We chose the brand name drug Aricept and its GE form donepezil to investigate, from a long term caregiver's perspective, the influence of both drugs on the patients' QOL. Methods: An EuroQo1-5 Dimension (EQ-5D) was used to assess the QOL of patients with Alzheimer's disease, before and after various Aricept and/or donepezil regimens, Patients were divided into four groups: first time users of Aricept (n=43), first time users of GE donepezil (n=45), users refilling previous prescriptions of Aricept (n=51), and users switching from Aricept to GE donepezil (n=51). Results: The average change in the EQ-5D utility indices rose significantly in the patients starting a new regimen of Aricept and its GE drug. The patients continuing an existing regimen of Aricept showed no significant differences, even after Aricept was switched to a GE drug. Conclusion: The QOL of patients starting a new regimen of Aricept and its GE drug improved, The QOL was maintained upon switching to the GE drug form.
引用
收藏
页码:174 / 179
页数:6
相关论文
共 50 条
  • [41] A review of quality of life in Alzheimer's disease Parts 1 and 2: Issues in assessing disease impact and drug effects
    Greer, M
    Monteban, H
    PHARMACOECONOMICS, 1999, 15 (06) : 641 - 641
  • [42] What’s in a Name? Use of Brand versus Generic Drug Names in United States Outpatient Practice
    Michael A. Steinman
    Mary-Margaret Chren
    C. Seth Landefeld
    Journal of General Internal Medicine, 2007, 22 : 645 - 648
  • [43] What's in a name? Use of brand versus generic drug names in United States outpatient practice
    Steinman, Michael A.
    Chren, Mary-Margaret
    Landefeld, C. Seth
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2007, 22 (05) : 645 - 648
  • [44] A Review of Quality of Life in Alzheimer’s DiseaseParts 1 and 2: Issues in Assessing Disease Impact and Drug Effects
    Marianne Greer
    Helma Monteban
    PharmacoEconomics, 1999, 15 (6) : 641 - 641
  • [45] A Review of Quality of Life in Alzheimer’s DiseaseParts 1 and 2: Issues in Assessing Disease Impact and Drug Effects
    Stephen P. McKenna
    Lynda C. Doward
    PharmacoEconomics, 1999, 16 : 417 - 417
  • [46] Clinical and economic consequences in patients initiating therapy with clopidogrel brand-name vs. generic: A real-life retrospective study
    Sicras-Mainar, A.
    Escobar-Cervantes, C.
    Mico-Perez, R. M.
    Llisterri-Caro, J. L.
    MEDICINA DE FAMILIA-SEMERGEN, 2020, 46 (01): : 16 - 26
  • [47] A Review of Quality of Life in Alzheimer’s DiseasePart 2: Issues in Assessing Drug Effects
    Sam S. Salek
    Melvyn D. Walker
    Antony J. Bayer
    PharmacoEconomics, 1998, 14 : 613 - 627
  • [48] Canadian parliament reviewing C-91 - Generic manufacturers want shorter drug patent term; Brand-name industry wants term extended
    不详
    BIOTECHNOLOGY LAW REPORT, 1997, 16 (03): : 371 - 371
  • [49] Geroprotective effects of Alzheimer's disease drug candidates
    Kepchia, Devin
    Currais, Antonio
    Dargusch, Richard
    Finley, Kim
    Schubert, David
    Maher, Pamela
    AGING-US, 2021, 13 (03): : 3269 - 3289
  • [50] Sleep quality in caregivers of patients with Alzheimer's disease and Parkinson's disease and its relationship to quality of life
    Cupidi, Chiara
    Realmuto, Sabrina
    Lo Coco, Gianluca
    Cinturino, Antonio
    Talamanca, Simona
    Arnao, Valentina
    Perini, Valentina
    D'Amelio, Marco
    Savettieri, Giovanni
    Lo Coco, Daniele
    INTERNATIONAL PSYCHOGERIATRICS, 2012, 24 (11) : 1827 - 1835